61 related articles for article (PubMed ID: 23745524)
41. Chalcones in cancer: understanding their role in terms of QSAR. II part.
Repanas A; Katsori AM; Hadjipavlou-Litina D
Mini Rev Med Chem; 2013 Jun; 13(7):952-70. PubMed ID: 22876949
[TBL] [Abstract][Full Text] [Related]
42. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
43. A Review on Mechanisms of Anti Tumor Activity of Chalcones.
Sharma R; Kumar R; Kodwani R; Kapoor S; Khare A; Bansal R; Khurana S; Singh S; Thomas J; Roy B; Phartyal R; Saluja S; Kumar S
Anticancer Agents Med Chem; 2015; 16(2):200-11. PubMed ID: 25980813
[TBL] [Abstract][Full Text] [Related]
44. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids.
Nepali K; Sharma S; Sharma M; Bedi PM; Dhar KL
Eur J Med Chem; 2014 Apr; 77():422-87. PubMed ID: 24685980
[TBL] [Abstract][Full Text] [Related]
45. Identification of quinoline-chalcones and heterocyclic chalcone-appended quinolines as broad-spectrum pharmacological agents.
Atukuri D; S V; R S; L V; R P; M M R
Bioorg Chem; 2020 Dec; 105():104419. PubMed ID: 33142228
[TBL] [Abstract][Full Text] [Related]
46. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?
Boumendjel A; Ronot X; Boutonnat J
Curr Drug Targets; 2009 Apr; 10(4):363-71. PubMed ID: 19355861
[TBL] [Abstract][Full Text] [Related]
47. Early investigational tubulin inhibitors as novel cancer therapeutics.
Nepali K; Ojha R; Lee HY; Liou JP
Expert Opin Investig Drugs; 2016 Aug; 25(8):917-36. PubMed ID: 27186892
[TBL] [Abstract][Full Text] [Related]
48. Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents.
Zhao TT; Xu YQ; Hu HM; Gong HB; Zhu HL
Curr Med Chem; 2019; 26(37):6786-6796. PubMed ID: 30417769
[TBL] [Abstract][Full Text] [Related]
49. Chalcones in cancer: understanding their role in terms of QSAR.
Katsori AM; Hadjipavlou-Litina D
Curr Med Chem; 2009; 16(9):1062-81. PubMed ID: 19275612
[TBL] [Abstract][Full Text] [Related]
50. Recent developments in biological aspects of chalcones: the odyssey continues.
Rani A; Anand A; Kumar K; Kumar V
Expert Opin Drug Discov; 2019 Mar; 14(3):249-288. PubMed ID: 30773996
[TBL] [Abstract][Full Text] [Related]
51. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
52. Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence.
Michalkova R; Mirossay L; Kello M; Mojzisova G; Baloghova J; Podracka A; Mojzis J
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373500
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, Structural and Biological Properties of the Ring-A Sulfonamido Substituted Chalcones: A Review.
Mphahlele MJ
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641467
[TBL] [Abstract][Full Text] [Related]
54. Multi-objective optimization methods in drug design.
Nicolaou CA; Brown N
Drug Discov Today Technol; 2013 Sep; 10(3):e427-35. PubMed ID: 24050140
[TBL] [Abstract][Full Text] [Related]
55. Assessment of the antineoplastic potential of chalcones in animal models.
Roman BI; Heugebaert TS; Bracke ME; Stevens CV
Curr Med Chem; 2013; 20(2):186-221. PubMed ID: 23244582
[TBL] [Abstract][Full Text] [Related]
56. Dihydrochalcones as Antitumor Agents.
De Luca F; Di Chio C; Zappalà M; Ettari R
Curr Med Chem; 2022 Aug; 29(30):5042-5061. PubMed ID: 35430969
[TBL] [Abstract][Full Text] [Related]
57. Brine shrimp lethality assay 'an effective prescreen': microwave-assisted synthesis, BSL toxicity and 3DQSAR studies-based designing, docking and antitumor evaluation of potent chalcones.
Nazir S; Ansari FL; Hussain T; Mazhar K; Muazzam AG; Qasmi ZU; Makhmoor T; Noureen H; Mirza B
Pharm Biol; 2013 Sep; 51(9):1091-103. PubMed ID: 23745524
[TBL] [Abstract][Full Text] [Related]
58. Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity.
Mirzaei H; Emami S
Eur J Med Chem; 2016 Oct; 121():610-639. PubMed ID: 27318983
[TBL] [Abstract][Full Text] [Related]
59. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
60. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly.
Ducki S
Anticancer Agents Med Chem; 2009 Mar; 9(3):336-47. PubMed ID: 19275525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
